[{"from": "human", "value": "Provide a brief overview of this molecule. [C][N][C][C][N][Branch1][Branch1][C][C][Ring1][=Branch1][C][C][C][O][C][=C][Branch2][Ring2][Branch1][C][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][N][=C][C][=Branch2][Ring1][Branch1][=C][Ring1][#Branch1][N][C][=C][C][=Branch1][#Branch2][=C][Branch1][=Branch1][C][=C][Ring1][=Branch1][Cl][Cl][O][C][C][#N][O][C]"}, {"from": "gpt", "value": "The molecule is a Bcr-Abl kinase inhibitor for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Compared to other tyrosine kinase inhibitors, it has a more favourable hematologic toxicity profile. FDA approved on September 4, 2012."}]